Viviane D.
- Country
- France
- Department
- 2404:Hématologie
Research Overview
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
- Phase IIIb Multicenter Open-Label Study of Asciminib Hydrochloride in Chronic Myelogenous Leukemia Patients in Chronic Phase Post-Two or More Tyrosine Kinase Inhibitors
Data & Insights
Has run more than one trial at 143 of 309 partner sites.
Specializations
Chronic Myeloid Leukemia Research
The investigator specializes in studying novel therapeutic approaches for Chronic Myeloid Leukemia (CML), with particular focus on treatment optimization and management strategies involving tyrosine kinase inhibitors (TKIs).
- TKI Discontinuation Strategies
- Advanced Phase CML Treatment
- Novel Therapeutic Combinations
Research extends to examining innovative treatments like asciminib and exploring therapeutic options for patients with specific mutations.
Myeloproliferative Disorders
Focuses on comprehensive treatment approaches for various myeloproliferative neoplasms, including research into both established and emerging therapies.
- Polycythemia Vera Management
- Essential Thrombocythemia Treatment
- Myelofibrosis Interventions
Investigates comparative effectiveness of treatments such as ruxolitinib and hydroxyurea in different myeloproliferative conditions.
Thrombosis Prevention
Conducts research on thromboembolic complication prevention in hematologic malignancies, with emphasis on anticoagulation strategies.
- Anticoagulation Protocols
- Risk Assessment Strategies
- Preventive Interventions
Studies the efficacy of various anticoagulant approaches in JAK2V617F-positive myeloproliferative disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.